
New On The Block
- Swiss life sciences giant Lonza Group is shopping its capsules and health ingredients division, and the shortlist is full of private equity heavy-hitters. In the running: Altaris, Lone Star Funds, and One Rock Capital. Expected sale price: At least €2.5 billion (US$2.8 billion). Think of it as a supplement aisle showdown—except the vitamins cost more than most small countries.